Vasculitis Treatment Market Size and Share
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 293.22 Million |
| Market Size (2030) | USD 357.26 Million |
| CAGR (2025 - 2030) | 4.03% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Vasculitis Treatment Market Analysis by Mordor Intelligence
The Vasculitis Treatment Market size is estimated at USD 293.22 million in 2025, and is expected to reach USD 357.26 million by 2030, at a CAGR of 4.03% during the forecast period (2025-2030).
Vasculitis, a rare condition involving blood vessel inflammation, is driving growth in its treatment market due to the rising prevalence of autoimmune and inflammatory disorders, advancements in biologics and targeted therapies, rising disposable incomes in emerging economies, expanding adoption of subcutaneous and oral biologic formulations, and a favorable regulatory framework.
As autoimmune and inflammatory diseases become more prevalent, the market is witnessing significant growth. ANCA-associated vasculitis (AAV), Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and other similar conditions are seeing a steady uptick in global incidence. For instance, as reported by the Institute for Health Metrics and Evaluation in August 2023, approximately 15% of the worldwide population aged over 30 is anticipated to be affected by osteoarthritis, with the number of cases projected to reach 1 billion by 2050. The global rise in aging populations exacerbates the challenges posed by autoimmune diseases. According to an October 2024 report from the World Health Organization (WHO), by 2030, one in six individuals globally will be 60 years or older. Additionally, forecasts suggest that by 2050, the population aged 60 and above will reach 2.1 billion, doubling from current levels. This demographic shift is crucial, given that the prevalence of many autoimmune disorders, including vasculitis, tends to increase with age.
Advances in biologics and targeted therapies have dramatically changed the course of treatment, resulting in a detour from chronic treatment with corticosteroids and non-selective immunosuppressants. Consider rituximab, for example. This CD20-targeted monoclonal antibody, originally developed for chronic B-cell malignancies, is now the definitive therapy for AAV. As of 2023, worldwide revenues of rituximab, including branded and biosimilar, surpassed USD 5.5 billion, with a significant share arising from its expanding use in autoimmune and orphan diseases.
Aging populations further exacerbate this phenomenon, especially in forms such as Giant Cell Arteritis (GCA) and ANCA-associated vasculitis (AAV), which are much more prevalent in people aged 50 years and older. The World Social Report 2023, published in January 2023, highlights that the global population aged 65 and above is forecasted to reach 1.5 billion by 2050, representing a significant increase from 771 million in 2022. In mature economies like North America, Europe, and Japan, this age bracket already makes up more than 20% of the population. These groups are associated with an increased incidence of vasculitis.
However, high biologics and targeted therapies costs, adverse effects and long-term safety concerns, and unawareness and misdiagnosis in emerging markets are expected to restrain market growth.
Global Vasculitis Treatment Market Trends and Insights
Corticosteroids Segment is Expected to Witness Significant Growth Over the Forecast Period
Corticosteroid drugs are well placed in clinical practice because of their anti-inflammatory, immunosuppressive, and anti-allergic action, rendering them a must-have in a broad array of medical illnesses. The corticosteroids segment is the largest based on its long history as the drug of choice for swift inflammation suppression. Their availability at a large scale, affordability, and ease of causing remission in large as well as small vessel vasculitis conditions further enhance uptake. Furthermore, clinical practice guidelines still support corticosteroids as the cornerstone of initial management, frequently combined with immunosuppressants.
Corticosteroids, known for their rapid anti-inflammatory effects, continue to be a primary choice in treating vasculitis. The frequent prescription of drugs like prednisone, especially for ANCA-associated vasculitis, underscores the segment's resilience and significance in the market. Concurrently, the market is seeing heightened investment in new therapies that promise more targeted, long-lasting, and steroid-sparing therapies. For example, in October 2023, Nkarta announced that it had received FDA clearance for its Investigational New Drug (IND) filing to study NKX019, an allogeneic natural killer (NK) cell therapy, for autoimmune diseases such as ANCA-associated vasculitis. The start of clinical studies marks a strategic push toward innovative immunotherapies, echoing wider industry momentum in the direction of innovation and personalized medicine in autoimmune disease treatment.
Clinical practice guidelines continue to endorse corticosteroids as the primary choice for induction therapy. For instance, as per updated 2024 guidelines of the Kidney Disease Improving Global Outcomes (KDIGO), for treating ANCA-associated vasculitis (AAV), glucocorticoids in combination with rituximab or cyclophosphamide were suggested to be used as initial treatment of new-onset AAV. Importantly, based on new efficacy and safety data, there's a growing preference for rituximab over cyclophosphamide in specific scenarios. Furthermore, the guidelines highlight Avacopan, a complement 5a receptor blocker, as a potential substitute for glucocorticoids. This is especially relevant for patients at heightened risk of steroid-induced side effects. Such conditions are undermining the growth of the corticosteroid segment.
North America is Expected to Dominate the Vasculitis Treatment Market
North America is set to dominate the market, driven by several key factors. These include a surge in autoimmune disease cases and heightened awareness among both patients and healthcare professionals. The region's advanced healthcare infrastructure, strong reimbursement frameworks, and easy access to FDA-approved biologics have further boosted treatment adoption. According to data from the Mayo Clinic, released in January 2025, approximately 15 million individuals in the United States were diagnosed with one or more of 105 autoimmune diseases, with a notably higher prevalence among women.
Moreover, the market is witnessing growth, fueled by an aging population and advancements in diagnostic technologies. For instance, as per January 2024 projections from the Population Reference Bureau, by 2040, nearly 80 million Americans, accounting for approximately 22% of the population, will be aged 65 and older. Similarly, imaging techniques like PET/CT, MRI, and CT angiography play a crucial role in detecting vascular inflammation linked to different forms of vasculitis.
Leading drug companies are actively investing in new treatments, driving the market forward, alongside continuous clinical studies. For example, in September 2024, Genentech, a subsidiary of the Roche Group, is conducting clinical trials of GAZYVA (obinutuzumab) in combination with corticosteroids to enhance therapeutic efficacy and reduce dependency on long-term steroid use in the treatment of ANCA-associated vasculitis.
Additionally a sophisticated healthcare infrastructure significantly contributes to economic activity by supporting early diagnosis, better disease management, and innovation in medical technologies. According to data released by the American Medical Association in April 2025, healthcare spending in the United States rose by 7.5% in 2023, reaching USD 4.9 trillion. Of this total, approximately 9.2%, equivalent to USD 449.7 billion, was allocated specifically to prescription drugs. This robust healthcare infrastructure significantly contributes to economic activity by fostering innovation in medical technologies and improving population health outcomes.
Therefore, owing to the factors mentioned above, the growth of the studied market is anticipated in the North American region.
Competitive Landscape
The vasculitis market is moderately consolidated, with key players strategizing to capture the majority stake of the market. The competitive landscape includes an analysis of a few international as well as local companies which hold significant market share and are well known, including Amneal Pharmaceuticals, Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd, GSK plc, Pfizer Inc., among others.
These market players are leveraging strategic partnerships, mergers, and acquisitions to enhance their competitive standing. Furthermore, they are prioritizing investments in research and development for innovative treatment solutions and expanding their presence across key geographic markets to drive growth.
Vasculitis Treatment Industry Leaders
-
Amneal Pharmaceuticals, Inc
-
AstraZeneca plc
-
F. Hoffmann-La Roche Ltd
-
GSK PLC
-
Pfizer Inc
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- June 2024: The United States FDA granted Phase II clinical trial approval to NovelMed's ruxoprubart, marking it as a pioneering therapy for ANCA-associated vasculitis (AAV).
- December 2023: Evotec SE entered into a collaboration with Charité – Universitätsmedizin Berlin to develop a detailed molecular patient database for ANCA-associated vasculitis (AAV). This collaboration seeks to harness Evotec's panomics technologies, aiming to refine patient stratification and guide precision medicine drug discovery for AAV.
Research Methodology Framework and Report Scope
Market Definitions and Key Coverage
Our study defines the vasculitis treatment market as all prescription pharmaceutical products, corticosteroids, traditional immunosuppressants, and biologic or targeted agents, marketed to manage primary vasculitic disorders across small, medium, and large-vessel categories. The value reflects ex-manufacturer revenue generated from new and refilled prescriptions supplied through hospital, retail, and online channels during the calendar year.
Scope exclusion: Supportive therapies used solely for comorbid autoimmune conditions are not included.
Segmentation Overview
- By Drug Class
- Corticosteroids
- Immunosuppressants
- Biologics
- By Disease Type
- Small Vessel Vasculitis
- Medium Vessel Vasculitis
- Large Arteries Vasculitis
- By Route of Administration
- Intramuscular & Subcutaneous
- Intradermal
- Oral
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail
- Online
- By End-User
- Hospitals
- Speciality Clinics
- Academic and Research Institutes
- Other End-Users
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East
- GCC
- South Africa
- Rest of Middle East
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Detailed Research Methodology and Data Validation
Primary Research
Analysts interview practicing rheumatologists, hospital pharmacists, and payer representatives across North America, Europe, and Asia-Pacific. These discussions validate prevalence assumptions, real-world step-therapy patterns, and average dosing schedules, allowing us to refine adoption curves for emerging biologics.
Desk Research
We first compile publicly available disease-burden data from sources such as the CDC, Eurostat, the Global Burden of Disease database, and national rheumatology registries. We then layer in treatment-utilization signals from FDA and EMA approval archives, clinical-trial repositories, and peer-reviewed journals. Annual reports, 10-Ks, and investor decks help our analysts gauge pricing strategy and pipeline timing, while paid platforms like D&B Hoovers and Dow Jones Factiva enrich competitive intelligence. This list is illustrative; many additional secondary sources inform data cleaning and cross-checks.
Market-Sizing & Forecasting
A top-down prevalence-to-treated-cohort model converts incident and prevalent patient pools into demand, which is then corroborated through selective bottom-up checks such as sampled average selling price multiplied by prescription volume from distributor audits. Core variables in the model include ANCA-associated vasculitis prevalence, average induction-to-maintenance switch rate, branded biologic share, therapy discontinuation ratio, and annual drug price revision. Forecasts to 2030 employ multivariate regression complemented by scenario analysis to reflect differing biologic penetration speeds and regional reimbursement shifts. Where bottom-up data are sparse, gap fills adopt conservative midpoint estimates validated by key opinion leaders.
Data Validation & Update Cycle
Outputs undergo variance tests against independent reimbursement spending, with anomalies escalated for senior review before sign-off. Mordor Intelligence refreshes every study annually and triggers an interim update when material events, such as a pivotal biologic approval, occur. An analyst performs a final sense check just before release so clients always receive our latest view.
Why Mordor's Vasculitis Treatment Baseline Inspires Confidence
Published market values often diverge because firms choose different disorder scopes, patient-conversion ratios, and currency year bases.
Key gap drivers include whether late-stage pipeline drugs are counted, the aggressiveness of biologic price erosion assumptions, and refresh cadence differences that influence exchange-rate conversions and inflation adjustments.
Benchmark comparison
| Market Size | Anonymized source | Primary gap driver |
|---|---|---|
| USD 293.22 million (2025) | Mordor Intelligence | |
| USD 250.09 million (2024) | Global Consultancy A | excludes hospital-dispensed generics and applies flat biologic pricing through 2032 |
| USD 250.1 million (2021) | Industry Journal B | relies on historical CAGR extrapolation without treated-cohort validation |
In sum, our disciplined scope definition, dual-path modeling, and yearly refresh cycle give decision-makers a transparent, balanced baseline that is traceable to clear variables and repeatable steps. This is why stakeholders trust Mordor's numbers for planning and benchmarking.
Key Questions Answered in the Report
How big is the Vasculitis Treatment Market?
The Vasculitis Treatment Market size is expected to reach USD 293.22 million in 2025 and grow at a CAGR of 4.03% to reach USD 357.26 million by 2030.
What is the current Vasculitis Treatment Market size?
In 2025, the Vasculitis Treatment Market size is expected to reach USD 293.22 million.
Who are the key players in Vasculitis Treatment Market?
Amneal Pharmaceuticals, Inc, AstraZeneca plc, F. Hoffmann-La Roche Ltd, GSK PLC and Pfizer Inc are the major companies operating in the Vasculitis Treatment Market.
Which is the fastest growing region in Vasculitis Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Vasculitis Treatment Market?
In 2025, the North America accounts for the largest market share in Vasculitis Treatment Market.
What years does this Vasculitis Treatment Market cover, and what was the market size in 2024?
In 2024, the Vasculitis Treatment Market size was estimated at USD 281.40 million. The report covers the Vasculitis Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Vasculitis Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on:
Vasculitis Treatment Market Report
Statistics for the 2025 Vasculitis Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Vasculitis Treatment analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
